Stay updated with breaking news from Nasdaq Mxct. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Valmark Advisers Inc. bought a new stake in MaxCyte, Inc. (NASDAQ:MXCT – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 83,927 shares of the company’s stock, valued at approximately $394,000. Valmark Advisers Inc. owned about 0.08% of MaxCyte […]
Stephens reaffirmed their overweight rating on shares of MaxCyte (NASDAQ:MXCT – Free Report) in a report published on Tuesday, Benzinga reports. The firm currently has a $11.00 price target on the stock. Several other equities analysts have also recently weighed in on the company. BTIG Research lowered their price target on MaxCyte from $10.00 to […]
Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs...
ROCKVILLE, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing...
MaxCyte, Inc. (NASDAQ:MXCT – Get Free Report) Director John Joseph Johnston sold 5,000 shares of MaxCyte stock in a transaction on Friday, January 26th. The shares were sold at an average price of $5.12, for a total transaction of $25,600.00. Following the completion of the sale, the director now owns 120,583 shares in the company, […]